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36 E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3and -49(G > T) from the transcription start site. We could demon-
strate that the variants -186(GGGC)5 (p < 0.05), and -49T (p = 0.05)
were significantly or strongly associated with colorectal cancer
as compared to the healthy controls. We found the highest pro-
moter activity to be associated with -186(GGGC)3 and -49T.
Conclusion: These results suggest that the two pKi-67 promoter
polymorphisms 186(GGGC)3 > (GGGC)5 and -49G > T located in the
basic promoter may play a crucial rule in the development of
colorectal cancer.
doi:10.1016/j.ejcsup.2006.04.084
P25. MATRIX METALLOPROTEINASE 9 SINGLE NUCLEOTIDE
POLYMORPHISM ANALYSIS IN BLOOD OF UROLOGICAL
CANCER PATIENTS
D. Stanciute, J. Didziapetriene, F. Jankevicius. Institute of Oncology,
Vilnius University, Lithuania.
Introduction: Ample evidence indicates that MMPs contribute in
multiple ways to all stages of malignant progression, including
tumor invasion, blood vessel penetration, metastases and tumor
angiogenesis. MMP-9 has been found to be specifically associated
with prostate cancer metastasis. A number of DNA polymor-
phisms in the MMP genes are associated with differences in
MMP activity. However, the relationship between the polymor-
phism and susceptibility of cancer remains ambiguous. A cyto-
sine (C) – thymidine (T) single nucleotide polymorphism (SNP)
at position -1562 in the MMP-9 promoter is reported to affect
expression of this gene.
Aim: To determine the prevalence of a single nucleotide poly-
morphism (-1562 C/T) in the MMP-9 gene promoter in cancer
patients and evaluate it’s correlation with tumor type and stage.
Methods and Materials: DNA from the cancer patients’ blood
was extracted and amplified with PCR. PCR-RFLP method was
used to determine MMP-9 polymorphism in 18 prostate cancer
cases, 4 benign prostate hyperplasia cases, 14 invasive bladder
cancer cases, 5 non-invasive bladder cancer cases, 4 renal cancer
cases and 1 adrenal gland cancer case.
Results: Prevalence of C/C, C/T, T/T genotypes was similar
among bladder and renal cancer patients. In prostate cancer
patients a significant association (P = 0.0052) between clinical
stage and MMP-9 polymorphism was found.
Conclusion: Our data demonstrate that MMP-9 (-1562 C/T) poly-
morphism may modify susceptibility to prostate cancer. We
hypothesized that this polymorphism might act as a genetic
modifier in the development and progression of prostate cancer.
Additional studies with larger population are warranted.
doi:10.1016/j.ejcsup.2006.04.085
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Background: Despite compelling data demonstrating a direct
link between altered expression of S100 proteins located on
human chromosome 1q21 and epithelial malignancies, the
knowledge of their function and mode of action in epithelial cells
and in tumor promotion or progression is largely unknown.
Methods: Gene expression profiling of the in vivo model of
chemically induced skin carcinogenesis revealed differential reg-
ulation of genes coding for S100 proteins. Subsequent studies
using in vitro models and tissue microarrays are currently
extended by to suitable in vivo models.
Results: Here, we have identified a novel signaling pathway in
epithelial cells initiated by extracellular S100A8/A9 resulting in
the activation of AP-1-dependent gene expression. Importantly,
co-expression of S100A3 inhibits S100A8/A9 mediated AP-1 acti-
vation, which is in line with repression of this gene during skin
carcinogenesis suggesting a negative role for S100A3 in epithelial
malignancy. We found elevated levels of MMP2 and MMP9, two
well-known AP-1 regulated genes, and identified S100A6 as an
additional target gene of S100A8/A9 signaling. Moreover, signifi-
cant co-expression of S100A8 and S100A9 together with phos-
phorylation of c-Jun and elevated S100A6 protein levels were
evident in eSCC. The in vivo relevance of S100A8/A9 interaction
with RAGE is discussed.
Conclusion: Our data suggest that targeting the net activity of
S100 induced signaling represents an auspicious strategy for can-
cer prevention and/or therapy.
doi:10.1016/j.ejcsup.2006.04.086
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Background: One of the most common properties of cancer is
genomic instability, a leading cause of which are defects of the
DNA damage response (DDR). DDR defects in tumors and germ-
line have been linked to clinical outcome and cancer susceptibil-
ity, respectively. Among DDR regulators, the nuclear checkpoint
kinase Chk1 is an established transducer of ATR- and ATM-
dependent signalling in response to DNA damage. Additional
functions of Chk1 include regulation of unperturbed cell cycle
progression. Recently, we have shown that Chk1 localizes to inter-
E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3 37phase centrosomes and thereby negatively regulates entry into
mitosis by preventing premature activation of cyclin B-Cdk1
[Nat Cell Biol 2004;6:884–91].
Methods: In synchronized U2OS cells, we inhibited Chk1 kinase
by the specific inhibitor CEP-3891 and manipulated this system
using different constructs and siRNAs.
Results: Chk1 inhibition induced premature mitotic entry dis-
playing regular spindles but deficient chromatin condensation –
which we have termed the ‘paraspindle’ phenotype –, apparently
resulting in mitotic nuclear fragmentation. The paraspindle phe-
notype was reverted by inhibition of the Cdc25B phosphatase
using siRNA, which restored normal mitoses with regular chro-
mosome condensation.
Conclusion: Cdc25B is an important downstream target of Chk1
in the regulation of mitotic entry. Our data may help elucidate the
mechanism of genomic instability as an early step in
carcinogenesis.
doi:10.1016/j.ejcsup.2006.04.087
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Background: Calpains are a family of 14 known intracellular cal-
cium dependent cysteine proteases that share a similar catalytic
structure. Calpains are involved in several key aspects of migra-
tion, including: adhesion and spreading; detachment of the rear;
and membrane protrusion. The best described calpains are l and
M calpain which are ubiquitous heterodimeric proteins composed
of a distinct catalytic subunit and a common regulatory subunit
called regulatory calpain (CSS1). Studies have shown the impor-
tance of CSS1 for the function of both l and M calpains. So far
there is not much known about the promoter and transcriptional
regulation of this important gene, therefore we conducted the fol-
lowing study to characterize the promoter and major cis acting
elements in the 5 0 prime region of CSS1 gene.
Methods: Different CSS1 promoter regions spanning 2.0 kb 5 0
upstream and 1.0 kb downstream region from the transcription
start site were PCR amplified using Hela cell genomic DNA, cloned
into pGEMT-Easy cloning vector, and sequenced. Luciferase repor-
ter constructs were made by subcloning these fragments into
pGL3-Basic vector. Luciferase assay was carried out in Hela,
MCF7 and HCT116 cell lines. EMSA and supershift with specific
antibodies was done using the standard protocol. TRANSFAC
database was used to scan the sequence for putative transcrip-
tion factor binding sites.
Results: All the three cell lines tested showed high constitute
expression of CSS1 mRNA and showed more or less similar pat-
tern of promoter activity for different deletion constructs of
CSS1, with construct 121 to +274 showing the highest activity.
Region 55 to 25 seems to be important for the core promoteractivity, this region contains a putative NRF1 biding site. NRF1
was found to bind to this region in EMSA. Interestingly, deletion
construct 55 to 2 which has lost the first noncoding exonic
region showed complete lack of promoter activity, suggesting that
the first noncoding exon containing putative AP-1-and Ets-1-
binding sites is required for basal promoter activity. Binding of
AP-1-transcription factors to this exonic region has already been
confirmed in gelshift analysis.
Conclusion: This study describes for the first time the minimal
region required for the basal activity of CSS1 promoter and defines
cis-elements and transcription factors regulating this vital gene.
doi:10.1016/j.ejcsup.2006.04.088
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Background: Circulating cell detection using RT-PCR techniques
has been studied as new prognostic factor in prostatic cancer
patients. To enhance detection sensitivity of these techniques,
we have developed a new multiplex RT-PCR assay for prostate cir-
culating cell detection based on the combined expression of KLK3
(formerly PSA), FOLH1 (formerly PSAM), PSCA, KLK2 and KLK15
(formerly prostinogen).
Methods: Our approach associate classical RT-PCR technics,
fluorescent labelling and a very sensitive capillary electrophoresis
detection. After RT-PCR, PCR products are visualized using capil-
lary electrophoresis and fluorescent detection which is very reli-
able to indicate the precise size of the detected fluorescent
products. We first test our new detection technique using prostate
cancer cell lines known to express all of these genes and
improved its sensibility using serial dilution of these cells in
healthy blood samples: the limit of detection was found to be as
few as 1 expressing cell in 106 nucleated blood cells. Between July
2005 and January 2006, 41 prostate cancer patients, 12 non pros-
tate cancer patients and 11 healthy individuals were included
and this multiplex RT-PCR assay was used to detect prostate cir-
culating cells.
Results: Multiplex RT-PCR assay was positive in 13/41 (32%) of
the prostate cancer patients for 3 of the 5 markers, whereas 4/
41 (10%) were found positive for 5 markers. The test was negative
for the 23 non prostate cancer patients or healthy individuals.
Conclusion: This multiplex RT-PCR assay with five markers
proved to be more sensitive than a single one in detecting prostate
circulating tumor cells. The discrepant expression of KLK3, FOLH1,
PSCA, KLK2 or KLK15 may label circulating tumor cells with differ-
ent levels of differentiation and subsequent aggressive behaviour,
and increases the capability to detect prostate circulating cells.
doi:10.1016/j.ejcsup.2006.04.089
